Page last updated: 2024-12-07

penicillin x

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

penicillin X: RN given refers to (2S-(2alpha,5alpha,6beta))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID120720
CHEBI ID81065
SCHEMBL ID5930569
MeSH IDM0114211

Synonyms (19)

Synonym
4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-6-(2-(p-hydroxyphenyl)acetamido)-7-oxo-
p-hydroxybenzylpenicillin
penicillin x
penicillin iii
brn 0049686
C17404
525-91-7
unii-w097a2s1du
w097a2s1du ,
4-27-00-05890 (beilstein handbook reference)
benzylpenicillin (benzathine) tetrahydrate impurity g [ep impurity]
penicillin g sodium impurity c [ep impurity]
benzathine benzylpenicillin impurity g [ep impurity]
(2s,5r,6r)-6-(2-(4-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid
4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((2-(4-hydroxyphenyl)acetyl)amino)-3,3-dimethyl-7-oxo-, (2s,5r,6r)-
SCHEMBL5930569
CHEBI:81065
DTXSID20200505
Q27155022

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" In both man and rabbit, penicillin X provided higher and more sustained blood levels than did penicillins F or G similarly administered in equal dosage (0."( THE VARYING BLOOD LEVELS AFFORDED BY PENICILLINS F, G, K, AND X IN RABBITS AND MAN.
Eagle, H, 1947
)
0.53
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
penicillinAny member of the group of substituted penams containing two methyl substituents at position 2, a carboxylate substituent at position 3 and a carboxamido group at position 6.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-199023 (92.00)18.7374
1990's2 (8.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.01 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index37.53 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]